# TNFRSF6B

## Overview
TNFRSF6B is a gene that encodes the protein known as Decoy Receptor 3 (DcR3), a member of the tumor necrosis factor receptor superfamily. Unlike many other members of this family, DcR3 is a soluble receptor, lacking a transmembrane domain, which allows it to circulate freely in the extracellular environment. The protein is characterized by its cysteine-rich domains, which facilitate its binding to specific ligands such as Fas ligand, LIGHT, and TL1A. These interactions enable DcR3 to function as a decoy receptor, modulating immune responses and apoptosis by preventing these ligands from engaging with their respective cell surface receptors. The expression and regulation of TNFRSF6B have significant implications in various physiological and pathological contexts, including immune modulation and cancer progression (Lin2011Decoy; Perdigones2010Evidence; Yu1999A).

## Structure
TNFRSF6B, also known as Decoy Receptor 3 (DcR3), is a soluble protein that belongs to the tumor necrosis factor receptor superfamily. It is characterized by the presence of cysteine-rich domains (CRDs), which are a hallmark of the TNF receptor family. These CRDs are crucial for the protein's ability to bind ligands such as Fas ligand, LIGHT, and TL1A, thereby inhibiting their interaction with cell surface receptors (Perdigones2010Evidence). The protein lacks a transmembrane domain, distinguishing it from other members of the TNF receptor family (Perdigones2010Evidence).

The structural integrity of TNFRSF6B is maintained by a dense network of disulfide bridges within its CRDs, which are enriched in cysteine residues (Magis2012An). These disulfide bonds are essential for the stability and function of the protein. Post-translational modifications, such as glycosylation, are common in TNFRSF6B and play a role in its stability and function (Perdigones2010Evidence). Multiple splice variants of TNFRSF6B exist, which may differ in their ligand-binding capabilities, although specific details on these isoforms are not provided in the context (Perdigones2010Evidence).

## Function
TNFRSF6B, also known as Decoy Receptor 3 (DcR3), is a soluble receptor that plays a significant role in modulating immune responses and apoptosis. In healthy human cells, DcR3 is involved in neutralizing the biological effects of Fas ligand (FasL), LIGHT, and TL1A, which are members of the tumor necrosis factor superfamily. This neutralization prevents these ligands from interacting with their respective receptors, thereby inhibiting apoptosis and modulating immune responses (Hsieh2017Decoy; Lin2011Decoy).

DcR3 is expressed in various cell types, including granulosa cells, endometrial cells, theca cells, and undifferentiated primary keratinocytes. Its expression can be upregulated by factors such as ultraviolet light, epidermal growth factor, and transforming growth factor-α, suggesting roles in keratinocyte differentiation and egg fertilization (Hsieh2017Decoy). Although its expression is low in normal conditions, DcR3's ability to modulate immune responses and cell differentiation indicates potential physiological functions that are not yet fully understood (Hsieh2017Decoy).

DcR3 also influences cellular processes such as actin reorganization and cell adhesion, promoting the expression of adhesion molecules like ICAM-1 and VCAM-1, which are crucial for immune cell interactions and migration (Lin2011Decoy).

## Clinical Significance
TNFRSF6B, also known as Decoy Receptor 3 (DcR3), is implicated in various diseases due to its altered expression levels and interactions. Overexpression of TNFRSF6B is associated with tumor progression in cancers such as diffuse gliomas. In these tumors, TNFRSF6B acts as a risk factor, with a hazard ratio greater than 1, indicating its association with poorer survival outcomes. This suggests that TNFRSF6B may contribute to tumor progression by inhibiting apoptosis and promoting an immunosuppressive tumor microenvironment (Wang2022Comprehensive).

In head and neck squamous cell carcinoma (HNSCC), TNFRSF6B was excluded from analysis due to undetectable expression levels, indicating that its role in this cancer type might be limited or context-dependent (Long2021TNF). Similarly, in hepatocellular carcinoma (HCC), TNFRSF6B was excluded from studies due to low expression, suggesting that its clinical significance may vary across different cancer types (Hu2022Identification).

Overall, TNFRSF6B's role in cancer appears to be linked to its ability to modulate immune responses and apoptosis, with its overexpression potentially leading to adverse clinical outcomes in certain cancers.

## Interactions
TNFRSF6B, also known as DcR3, is a soluble decoy receptor that interacts with several ligands, including Fas ligand (FasL), LIGHT, and TNF-like molecule 1A (TL1A). These interactions inhibit the binding of these ligands to their functional receptors, thereby modulating immune responses and apoptosis pathways (Yu1999A). TNFRSF6B can bind to LIGHT and FasL, acting as a competitive inhibitor in the interaction between LIGHT and its receptors HVEM/TR2 and LTbR. This suggests a role in inhibiting apoptosis and modulating tumor activity (Yu1999A).

In the context of viral infections, the Epstein-Barr virus (EBV) transcription activator Rta has been shown to upregulate TNFRSF6B expression by binding to its promoter region. This interaction enhances TNFRSF6B expression during EBV reactivation, indicating a regulatory mechanism involving viral proteins and host gene expression (Ho2007EpsteinBarr). The binding of Rta to a specific Rta-responsive element (RRE) in the TNFRSF6B promoter is crucial for this upregulation (Ho2007EpsteinBarr). These interactions highlight the complex regulatory roles of TNFRSF6B in immune modulation and its potential involvement in viral pathogenesis.


## References


[1. (Ho2007EpsteinBarr) Cheng-Hsun Ho, Chen-Fang Hsu, Pei-Fen Fong, Shyh-Kuan Tai, Shie-Liang Hsieh, and Chi-Ju Chen. Epstein-barr virus transcription activator rta upregulates decoy receptor 3 expression by binding to its promoter. Journal of Virology, 81(9):4837–4847, May 2007. URL: http://dx.doi.org/10.1128/jvi.02448-06, doi:10.1128/jvi.02448-06. This article has 22 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/jvi.02448-06)

[2. (Hu2022Identification) Yinan Hu, Jingyi Liu, Jiahao Yu, Fangfang Yang, Miao Zhang, Yansheng Liu, Shuoyi Ma, Xia Zhou, Jingbo Wang, and Ying Han. Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. Cancer Cell International, February 2022. URL: http://dx.doi.org/10.1186/s12935-022-02514-0, doi:10.1186/s12935-022-02514-0. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-022-02514-0)

[3. (Hsieh2017Decoy) Shie-Liang Hsieh and Wan-Wan Lin. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. Journal of Biomedical Science, June 2017. URL: http://dx.doi.org/10.1186/s12929-017-0347-7, doi:10.1186/s12929-017-0347-7. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s12929-017-0347-7)

[4. (Perdigones2010Evidence) Nieves Perdigones, Ana G. Vigo, José R. Lamas, Alfonso Martínez, Alejandro Balsa, Dora Pascual‐Salcedo, Emilio G. de la Concha, Benjamín Fernández‐Gutiérrez, and Elena Urcelay. Evidence of epistasis between tnfrsf14 and tnfrsf6b polymorphisms in patients with rheumatoid arthritis. Arthritis &amp; Rheumatism, 62(3):705–710, February 2010. URL: http://dx.doi.org/10.1002/art.27292, doi:10.1002/art.27292. This article has 17 citations.](https://doi.org/10.1002/art.27292)

[5. (Yu1999A) Kang-Yeol Yu, Byungsuk Kwon, Jian Ni, Yifan Zhai, Reinhard Ebner, and Byoung S. Kwon. A newly identified member of tumor necrosis factor receptor superfamily (tr6) suppresses light-mediated apoptosis. Journal of Biological Chemistry, 274(20):13733–13736, May 1999. URL: http://dx.doi.org/10.1074/jbc.274.20.13733, doi:10.1074/jbc.274.20.13733. This article has 305 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.274.20.13733)

[6. (Wang2022Comprehensive) Qiang-Wei Wang, Wei-Wei Lin, and Yong-Jian Zhu. Comprehensive analysis of a tnf family based-signature in diffuse gliomas with regard to prognosis and immune significance. Cell Communication and Signaling, January 2022. URL: http://dx.doi.org/10.1186/s12964-021-00814-y, doi:10.1186/s12964-021-00814-y. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-021-00814-y)

[7. (Lin2011Decoy) Wan-Wan Lin and Shie-Liang Hsieh. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochemical Pharmacology, 81(7):838–847, April 2011. URL: http://dx.doi.org/10.1016/j.bcp.2011.01.011, doi:10.1016/j.bcp.2011.01.011. This article has 126 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2011.01.011)

[8. (Magis2012An) Cedrik Magis, Almer M. van der Sloot, Luis Serrano, and Cedric Notredame. An improved understanding of tnfl/tnfr interactions using structure-based classifications. Trends in Biochemical Sciences, 37(9):353–363, September 2012. URL: http://dx.doi.org/10.1016/j.tibs.2012.06.002, doi:10.1016/j.tibs.2012.06.002. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2012.06.002)

[9. (Long2021TNF) Qian Long, Chunyu Huang, Qi Meng, Jin Peng, Fan Yao, Dingfu Du, Xiaonan Wang, Wancui Zhu, Dingbo Shi, Xiangdong Xu, Xiang Qi, Wuguo Deng, Miao Chen, Yizhuo Li, and Ankui Yang. Tnf patterns and tumor microenvironment characterization in head and neck squamous cell carcinoma. Frontiers in Immunology, October 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.754818, doi:10.3389/fimmu.2021.754818. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.754818)